The global severe asthma treatment market is expected to garner a market value of US$ 22 Billion in 2023 and is expected to accumulate a market value of US$ 36.18 Billion by registering a CAGR of 5.1% in the forecast period 2023 to 2033. Growth of the severe asthma treatment market can be attributed to growing prevalence of asthma along with wide presence of treatment options. The market for severe asthma treatment registered a CAGR of 3.3% in the historical period 2018 to 2022
Severe asthma is a chronic respiratory disease that affects a small percentage of asthma patients who experience persistent symptoms despite treatment with high doses of inhaled corticosteroids and other asthma medications. Severe asthma treatment aims to reduce symptoms and improve quality of life for patients who have difficulty controlling their asthma with conventional therapies.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 22 Billion |
| Anticipated Forecast Value (2033) | US$ 36.18 Billion |
| Projected Growth Rate (2023 to 2033) | 5.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Severe asthma treatment reflected a value of 3.3% during the historical period, 2018 to 2022.
The market was mainly driven by the increasing prevalence of severe asthma, the development of novel biologic therapies, and the rising awareness of the disease among patients and healthcare providers. The emergence of several biologic therapies for severe asthma, such as mepolizumab, reslizumab, benralizumab, and dupilumab are expected to drive market growth. Additionally, the availability of advanced diagnostic tools for the accurate diagnosis of severe asthma is likely to further boost market growth.
Thus, the market for Severe asthma treatment is expected to register a CAGR of 5.1% in the forecast period 2023 to 2033.
Development of innovative treatment options driving market growth
Asthma is a common chronic respiratory disease, and the number of people living with asthma is increasing worldwide. This is expected to drive demand for severe asthma treatment in the coming years. The development of new and innovative treatment options for severe asthma is expected to drive growth in the severe asthma treatment market. This includes the development of biologic medications and other targeted therapies that offer improved efficacy and fewer side effects compared to traditional asthma medications.
As healthcare spending continues to increase worldwide, there is expected to be a greater focus on the development and adoption of new treatments for chronic diseases like severe asthma. As awareness of severe asthma grows, more patients are being diagnosed with the condition. This is expected to drive demand for severe asthma treatment in the coming years.
Government initiatives and funding for research and development of new severe asthma treatments is expected to drive growth in the market. This includes initiatives aimed at improving access to care for patients with severe asthma, as well as funding for research into new treatment options.
Availability of medications boosting the development of severe asthma treatment market
Severe asthma treatment may involve a combination of medications, lifestyle changes, and specialized care from a team of healthcare professionals. Some of the most common treatments for severe asthma include
Principal Consultant
Regulatory challenges and lack of awareness derailing market growth
Severe asthma treatment can be expensive, especially biologic medications, which can cost thousands of dollars per year. This high cost can limit access to treatment for some patients, especially those in low-income countries or without adequate insurance coverage.
Severe asthma treatment often requires specialized care from a multidisciplinary team of healthcare professionals, including pulmonologists, allergists, and respiratory therapists. However, access to such specialized care may be limited in some regions, which can limit the availability of effective treatment options for severe asthma patients.
Although there are several treatment options available for severe asthma, some patients may not respond well to these treatments or may experience significant side effects. This can limit the efficacy of existing treatments and create a need for new and more effective therapies.
Many patients with severe asthma may not be aware of the full range of treatment options available to them, which can limit their ability to effectively manage their symptoms and improve their quality of life.
The severe asthma treatment market is highly regulated, which can create barriers to entry for new products and treatments. This can limit innovation in the market and restrict the availability of new and potentially more effective treatments for severe asthma.
Overall, the severe asthma treatment market faces several challenges, including high treatment costs, limited availability of specialized care, limited efficacy of existing treatments, lack of patient awareness, and regulatory challenges. Addressing these challenges will be critical to improving access to effective treatment options for patients with severe asthma.
Advancements in treatment options spurring growth of severe asthma treatment
The North America severe asthma treatment market is expected to grow significantly in the coming years due to several factors, including the high prevalence of asthma in the region, increasing awareness and diagnosis of severe asthma, and advancements in treatment options.
In the United States, an estimated 25 Billion people have asthma, and approximately 5-10% of these individuals have severe asthma that is difficult to control with conventional treatments. This represents a significant patient population that is in need of specialized care and effective treatment options.
In recent years, there have been several advancements in severe asthma treatment options, including the development of biologic medications and other targeted therapies that offer improved efficacy and fewer side effects compared to traditional asthma medications. These advancements are expected to drive growth in the severe asthma treatment market in North America as more patients seek out and receive effective treatment. Thus, North America is expected to possess 45% market share for severe asthma treatment market in 2023.
Government initiatives aiming at improving treatment access for asthma patients in Europe
In Europe, an estimated 30 Billion people have asthma, and approximately 5-10% of these individuals have severe asthma that is difficult to control with conventional treatments. This represents a significant patient population that is in need of specialized care and effective treatment options.
In addition, the Europe severe asthma treatment market is expected to continue to grow in the coming years as more patients are diagnosed with severe asthma and as new and innovative treatment options become available. Additionally, government initiatives aimed at improving access to care and increasing awareness of severe asthma may also help to drive growth in the market. Thus, Europe is expected to possess 39% market share for severe asthma treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Easier accessibility to affected region maximizing use of inhalation therapy
Inhalation therapy is often the preferred route of administration for the treatment of severe asthma. Inhalation therapy includes the use of inhalers and nebulizers, is often the preferred route of administration for the treatment of severe asthma.
This is because inhalation therapy delivers medication directly to the lungs, where it can provide quick relief of asthma symptoms and target the underlying inflammation that causes asthma. Thus, inhaled route of administration is expected to possess 40% market share for severe asthma treatment market in 2023.
Key players in the severe asthma treatment market are Teva Pharmaceutical, AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Regeneron Pharmaceutical, 4D Pharma plc, AB Pharma, Morphosys, Roche, Avalo Therapeutics, Suzhou Connect Biopharmaceuticals, Pieris Pharma, Biosion
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 22 Billion |
| Market Value in 2033 | US$ 36.18 Billion |
| Growth Rate | CAGR of 5.1% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market is estimated to be valued at US$ 22 billion in 2023.
The key market players are AstraZeneca, GSK, and Teva.
India, Japan, and China dominate the Asian market.
The market is estimated to reach US$ 36.18 billion by 2033.
North America is projected to emerge as a lucrative market.
1. Executive Summary | Severe Asthma Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Reslizumab
5.3.2. Benralizumab
5.3.3. Anti-inflammatory
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Inhaled
6.3.3. Intravenous
6.3.4. Subcutaneous
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Device Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Device Type , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Device Type , 2023 to 2033
7.3.1. Dry powder inhalers
7.3.2. Metered dose inhalers
7.3.3. Soft mist inhalers
7.4. Y-o-Y Growth Trend Analysis By Device Type , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Device Type , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Device Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Device Type
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Device Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Device Type
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Device Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Device Type
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Device Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Device Type
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Device Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Device Type
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Device Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Device Type
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Drug Class
15.2.3. By Route of Administration
15.2.4. By Device Type
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Route of Administration
15.3.4. By Device Type
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Route of Administration
16.1.2.3. By Device Type
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Route of Administration
16.2.2.3. By Device Type
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Route of Administration
16.3.2.3. By Device Type
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Route of Administration
16.4.2.3. By Device Type
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Route of Administration
16.5.2.3. By Device Type
16.6. United kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Route of Administration
16.6.2.3. By Device Type
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Route of Administration
16.7.2.3. By Device Type
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Route of Administration
16.8.2.3. By Device Type
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Route of Administration
16.9.2.3. By Device Type
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Route of Administration
16.10.2.3. By Device Type
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Route of Administration
16.11.2.3. By Device Type
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Route of Administration
16.12.2.3. By Device Type
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Route of Administration
16.13.2.3. By Device Type
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Route of Administration
16.14.2.3. By Device Type
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Route of Administration
16.15.2.3. By Device Type
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Route of Administration
16.16.2.3. By Device Type
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Route of Administration
16.17.2.3. By Device Type
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Route of Administration
16.18.2.3. By Device Type
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Route of Administration
16.19.2.3. By Device Type
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Route of Administration
16.20.2.3. By Device Type
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Route of Administration
16.21.2.3. By Device Type
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Route of Administration
17.3.4. By Device Type
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Teva Pharmaceutical
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. AstraZeneca
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. GlaxoSmithKline
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Novartis
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Sanofi
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Regeneron Pharmaceutical
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. 4D Pharma plc
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. AB Pharma
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Morphosys
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Roche
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Avalo Therapeutics
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Suzhou Connect Biopharmaceuticals
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
18.1.13. Pieris Pharma
18.1.13.1. Overview
18.1.13.2. Product Portfolio
18.1.13.3. Profitability by Market Segments
18.1.13.4. Sales Footprint
18.1.13.5. Strategy Overview
18.1.13.5.1. Marketing Strategy
18.1.14. Biosion
18.1.14.1. Overview
18.1.14.2. Product Portfolio
18.1.14.3. Profitability by Market Segments
18.1.14.4. Sales Footprint
18.1.14.5. Strategy Overview
18.1.14.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Severe Asthma Treatment Market
